Biologic agents and ankylosing spondylitis (AS) Archives

Abstract Number: 2569 • ACR/ARHP Annual Meeting 2014
Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab
Jean-Pierre Raynauld¹, Louis Bessette², Denis Choquette¹, Isabelle Fortin³, Boulos Haraoui¹, Jean-Pierre Pelletier⁴, Marie-Anaïs Rémillard⁵, Diane Sauvageau¹, Edith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada
Background/Purpose: As much a 40% of patients with ankylosing spondylitis will fail (BASDAI≥ 4) different non-steroidal anti-inflammatory agents and will eventually be treated with an…

Abstracts tagged "Biologic agents and ankylosing spondylitis (AS)"